Burkhardt Laufer

Title: Burkhardt Laufer: Innovator in Cancer Imaging and Treatment

Introduction

Burkhardt Laufer is a notable inventor based in Munich, Germany. He has made significant contributions to the field of cancer imaging and treatment through his innovative research and development.

Latest Patents

Laufer holds a patent for a groundbreaking approach to cancer imaging and treatment. His patent involves compounds or conjugates that are useful for diagnostic imaging and therapeutic purposes. Each compound comprises a ligand for the chemokine receptor CXCR4 and a detectable label. The ligand exhibits a binding affinity for the CXCR4 receptor, measured as IC in the presence of I-CPCR4, of 250 nM or lower. Notably, the ligand includes a cyclic oligopeptide moiety featuring the motif B-Arg or B-(Me)Arg, where B is a basic amino acid, a derivative thereof, or phenylalanine.

Career Highlights

Burkhardt Laufer is affiliated with the Technische Universität München, where he continues to advance his research in cancer treatment technologies. His work has garnered attention for its potential to improve diagnostic and therapeutic outcomes for cancer patients.

Collaborations

Laufer collaborates with esteemed colleagues such as Hans Jürgen Wester and Norman Koglin, contributing to a dynamic research environment focused on innovative cancer solutions.

Conclusion

Burkhardt Laufer's contributions to cancer imaging and treatment exemplify the impact of innovative research in medicine. His work not only enhances diagnostic capabilities but also paves the way for more effective therapeutic strategies.